As reported at the European Society for Medical Oncology (ESMO) Congress 2019 and simultaneously in The New England Journal of Medicine by Hellmann et al, the phase III CheckMate 227 trial has shown that nivolumab plus ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with programmed cell death ligand 1 expression ≥ 1%, a co-primary endpoint of the trial.
Exposure to e-cigarette smoke caused mice to develop lung cancer, according to findings from a preclinical study published by Tang et al in the Proceedings of National Academy of Sciences of the United States of America (PNAS).
Patients with ALK-positive non–small cell lung cancer (NSCLC) that was metastatic to the brain at baseline demonstrated whole-body, intracranial, and extracranial responses following treatment with ceritinib, according to findings from the phase II ASCEND-7 study presented by Chow et al at the European Society for Medical Oncology (ESMO) 2019 Congress.
Patients with advanced lung cancer might soon be offered a blood test that could help decide the best treatment for them, instead of relying on tumor biopsy analysis. New data from the BFAST trial presented by Gadgeel et al at the European Society for Medical Oncology (ESMO) Congress 2019.